Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph - Takeaways - MDSpire

Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph

  • By

  • Su, Meiyi

  • Tang, Yuqing

  • Sun, Pengtao

  • Cen, Huan

  • Liu, Shaonan

  • Li, Xianlun

  • Wang, Wei

  • Wang, Lei

  • June 10, 2026

  • 0 min

Share

  • 1

    Coronary microvascular disease (CMVD) is a leading cause of angina in patients with ischemia and nonobstructive coronary arteries.

  • 2

    Shexiang Tongxin Dropping Pill (STDP) has demonstrated protective effects on coronary microvasculature in preliminary studies.

  • 3

    This multicenter randomized trial will evaluate the efficacy and safety of STDP using cardiopulmonary exercise testing as the primary outcome.

  • 4

    The study will also develop an AI-assisted myocardial contrast echocardiography tool to enhance CMVD detection and classification.

  • 5

    The trial aims to provide high-quality evidence for STDP's use in CMVD and improve diagnosis and management of functional coronary ischemia.

Original Source(s)

Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph

  • by Su, Meiyi , Tang, Yuqing , Sun, Pengtao , Cen, Huan , Liu, Shaonan , Li, Xianlun , Wang, Wei , Wang, Lei

  • June 10, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis

Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study